Request Demo

Last update 08 May 2025

Complication of renal dialysis

Last update 08 May 2025

Basic Info

Synonyms

Complication of renal dialysis, Complication of renal dialysis (disorder)

Introduction-

Drugs associated with Complication of renal dialysis

Sirolimus

Target

mTOR

Mechanism

mTOR inhibitors

Active Org.

Santen Pharmaceutical Co., Ltd. [+30]

Originator Org.

Pfizer Inc.

Active Indication

Vascular Malformations [+94]

Inactive Indication

Acute Erythroblastic Leukemia [+123]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

United States

First Approval Date15 Sep 1999

Clinical Trials associated with Complication of renal dialysis

NCT05490225

/ Not yet recruitingNot Applicable

A Study to Evaluate the Safety and Effectiveness of Voyager's Access Device for Patients Undergoing Routine Hemodialysis (Access Cannulation Trial II)

This is a pivotal, interventional, prospective, single-arm, open-label, multi-site clinical investigation intended to support FDA clearance of the study device based on the safety and efficacy of the device in cannulating arteriovenous fistulas (AVFs) for hemodialysis procedures.

Start Date25 Mar 2025

Sponsor / Collaborator

Voyager Biomedical, Inc.

NCT06233838

/ RecruitingNot ApplicableIIT

Prospective, Multicenter, Randomized, Open Label Study on the Efficacy and Safety of Comparison of KHA80 Blood Perfusion Combined With Hemodialysis and Conventional Hemodialysis in Clearing IL-6, β2-MG and PTH in Maintenance Hemodialysis Patients

To evaluate the decreasing rate of blood IL-6, β2-MG and PTH in maintenance hemodialysis patients in the 52nd week compared with routine hemodialysis.

Start Date13 Jan 2025

Sponsor / Collaborator

First Affiliated Hospital Of Fujian Medical University

IRCT20241112063678N1

/ RecruitingNot ApplicableIIT

Effect of Lavender, Peppermint and Rose Oil on Pain and Anxiety Associated with Arteriovenous Fistula Cannulation in Hemodialysis Patients

Start Date01 Dec 2024

Sponsor / Collaborator

University of Baghdad

100 Clinical Results associated with Complication of renal dialysis

100 Translational Medicine associated with Complication of renal dialysis

0 Patents (Medical) associated with Complication of renal dialysis

Literatures (Medical) associated with Complication of renal dialysis

01 Jan 2015·NephronQ4 · MEDICINE

Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia

Q4 · MEDICINE

Article

Author: Spasovski, Goce ; Wanner, Christoph ; Hertel, Joachim ; Dimkovic, Nada ; Locatelli, Francesco

Background/Aims: Colestilan is a new non-calcium-based phosphate binder licensed in Europe for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis (CKD 5D). This study was conducted to evaluate efficacy in a North American patient population and also to examine secondary actions of colestilan on lipid profile and glycated hemoglobin (HbA1c). Methods: This was a multicenter, randomized, double-blind, placebo-controlled withdrawal study, after an initial open-label titration period. Patients (n = 245) with stable phosphate control received 6-15 g/day colestilan during a 12-week, flexible titration period after which 169 were randomized to continue the same dose (n = 85) or switch to placebo (n = 84) for 4 weeks. The primary endpoint was the change in serum phosphorus level during the placebo-controlled withdrawal period. Results: A significant difference of -1.01 mg/dl (-0.33 mmol/l) in mean change in serum phosphorus, favoring colestilan, was seen during the placebo-controlled withdrawal period (p < 0.001). Colestilan reduced serum phosphorus significantly from baseline to week 12 (-1.54 mg/dl (-0.50 mmol/l); p < 0.001). Serum calcium levels were not affected. Colestilan significantly reduced and maintained reductions in calcium × phosphorus ion product (Ca × P), parathyroid hormone, total cholesterol, low-density lipoprotein cholesterol, uric acid and also HbA1c in patients with elevated baseline HbA1c. Colestilan was generally well tolerated; most adverse events were gastrointestinal. Conclusion: In this first clinical trial with colestilan in a North American patient population, colestilan demonstrated significant efficacy in controlling serum phosphorus levels in CKD 5D patients with hyperphosphatemia, without increasing calcium levels.

01 Jun 2002·International Journal of DermatologyQ4 · MEDICINE

Scleromyxedema‐like fibromucinosis in a patient undergoing hemodialysis

Q4 · MEDICINE

Review

Author: Anne Marie McNeill ; Ronald J. Barr

Fifteen hemodialysis patients were recently reported with a new scleromyxedema‐like fibrosing disorder thought to be associated with renal dialysis. A case of this new clinicopathological entity is described as well as a limited review of the literature relevant to this disease.The patient was a 31‐year‐old Hispanic female with firm cutaneous plaques with brawny hyperpigmentation on the thighs and arms, which started 1 month after starting hemodialysis therapy for end‐stage renal disease. There was no monoclonal gammopathy or evidence of systemic mucin deposition or other organ system disease.Histopathologically, the skin biopsy samples show haphazardly arranged dermal fibroblasts with associated collagen and small collections of interfibrillar mucin.The skin biopsy was interpreted as scleromyxedema‐like fibromucinosis. This represents an additional case of this new renal dialysis‐associated disorder. The disease may also occur in nondialysis patients, including those with liver disease.

01 Feb 1993·Archives of Dermatology

Hyperpigmentation, bullae, and keratotic papules in a renal dialysis patient. Pseudoporphyria cutanea tarda (PPCT), acquired perforating disorder of renal dialysis (APD)

Article

Author: Ross, M ; White, G M

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Complication of renal dialysis

Basic Info

Related

Analysis